<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We examined the possible prophylactic potential of HA1077, a calcium <z:chebi fb="68" ids="48706">antagonist</z:chebi> and <z:chebi fb="1" ids="35620">vasodilator</z:chebi>, on <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> induced in a two-<z:mp ids='MP_0001914'>hemorrhage</z:mp> canine model, and also its effects on cerebral hemodynamics </plain></SENT>
<SENT sid="1" pm="."><plain>The intravenous infusion of HA1077 3 mg/kg over 30 min twice daily (day 1-day 7) after the first intracisternal injection of 5 ml autologous blood significantly prevented the occurrence of <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The mean diameter of the basilar arteries on day 7 was 66.1 +/- 1.6% (n = 7) of the baseline before the intracisternal injection of blood, compared to 54.2 +/- 1.6% (n = 9) of the baseline in the untreated group (P less than 0.01) </plain></SENT>
<SENT sid="3" pm="."><plain>Bolus intravenous administration of HA1077 (0.1 and 0.3 mg/kg) dose dependently increased local cerebral blood flow </plain></SENT>
<SENT sid="4" pm="."><plain>Since HA1077 prevents the development of <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> after <z:hpo ids='HP_0002138'>subarachnoid hemorrhage</z:hpo> and improves hemodynamic functions, as manifested by increases in local cerebral blood flow, further study is warranted regarding the possible clinical use of this drug </plain></SENT>
</text></document>